CD95 ligand expression in dedifferentiated breast cancer

Journal of Pathology

Volumn 189, Issue 3, 1999, Pages 378-386

  Müschen, Markus ^a,b   Moers, Cordula ^a   Warskulat, Ulrich ^a   Niederacher, Dieter ^a   Betz, Beate ^a   Even, Jos ^b   Lim, Annick ^b   Josien, Régis ^c   Beckmann, Matthias W ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b INSTITUT PASTEUR   (France)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antitumour immunity; Apoptosis; Breast; Carcinoma; Differentiation; Tumour infiltrating lymphocytes

Indexed keywords

FAS ANTIGEN; MESSENGER RNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CLINICAL ARTICLE; DIFFERENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL DIFFERENTIATION; FAS LIGAND PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; JURKAT CELLS; LIGANDS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0345411407     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D     Document Type: Article

References (25)

1. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
2. Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429.
3. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
4. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
5. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996; 2: 317-322.
6. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777-1783.
7. Sato K, Kimura F, Nakamura Y, et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haemotol 1996; 94: 379-382.
8. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
9. Nakayima M, Nakajima A, Kayagaki N, Honda M, Yagita H, Okumura K. Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury. Clin Immunol Immunopathol 1997; 83: 223-229.
10. Keane MM, Ettenberg A, Lowrey GA, Russel EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-4798.
11. Cai Z, Stancou R, Körner M, Chouaib S. Impairment of Fas-antigen expression in adriamycin-resistant but not in TNF-resistant MCF-7 tumor cells. Int J Cancer 1996; 68: 535-546.
12. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870-3874.
13. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
14. Hahne M, Rimoldi D, Schröter M, et al. Melanoma cell expression of CD95 (Apo-1/Fas) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
15. Hug H. Fas-mediated apoptosis in tumor formation and defense. Biol Chem 1997; 378: 1405-1412.
16. Seino KI, Kayagari N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165-170.
17. Bennett MW, O'Connell JO, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675.
18. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nature Med 1997; 3: 843-848.
19. Pannetier C, Delassus S, Darche S, Saucier C, Kourilsky P. Quantitative titration of nucleic acids by enzymatic amplification reactions run to saturation. Nucleic Acids Res 1993; 21: 577-583.
20. Josien R, Douillard P, Guillot C, et al. A critical role for transforming growth fractor-β (TGF-β) in donor transfusion-induced allograft tolerance. J Clin Invest 1998; 102: 1920-1926.
21. Muschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (Apo-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology 1998; 27: 200-208.
22. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
23. Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367-1370.
24. Müschen M, Warskulat U, Schmidt B, Schulz WA, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by IFNγ and all-trans retinoic acid. Biol Chem 1998; 379: 1083-1091.
25. Moers C, Warskulat U, Müschen M, et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous cell carcinoma by interferon γ and cisplatin. Int J Cancer 1999; 80: 564-572.